Larvol Delta - N39FORCE-Phase-II-Study-of-Ficerafusp-Alfa-in-Combination-With-Nivolumab-in-Patients-With-Platinumrefractory-Head-and-Neck-Squamous-Cell-Carcinoma

ficerafusp alfa (BCA101) - Bicara Therapeutics

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

http://clinicaltrials.gov/ct2/show/NCT07529873

Apr 15, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next